WuXi AppTec’s wholly-owned subsidiary WuXi Advanced Therapies (WuXi ATU) has announced the launch of Tetracycline-Enabled Self-Silencing Adenovirus (TESSA) technology to improve scalability and accessibility of cell and gene therapies.
The new technology, which is developed by Oxgene, offers a scalable process to manufacture gene therapies.
It also helps to accelerate the production of therapeutic DNA required for the treatment of patients in need.
TESSA will expedite the manufacturing of adeno-associated virus (AAV) and reduce the costs to produce cell and gene therapies.
